Articles by Katie Anderson

  1. ISPE Awards 8 Innovative Pharma Facilities 10/31/2025

    The Facility of the Year Awards (FOYA) celebrates 20 years of innovation and excellence in 2025, and I had the pleasure of joining the celebration at the 2025 ISPE FOYA Banquet and Awards Celebration on Oct. 26, 2025.

  2. 9 Drugs Granted Fast Track By FDA's Voucher Program 10/23/2025

    With targets like pancreatic cancer, deafness, blindness, infertility and vaping addiction, these drugs were chosen due to an unmet need, addressing a public health crisis, boosting domestic manufacturing or increasing affordability.

  3. Leaders In The Excipient Market: Region And Type 10/21/2025

    Though North America led the market with a 38.32% market share of $3.15 billion in 2024, Asia Pacific is expected to have the fastest growth in the upcoming years.

  4. 3 [Potential] Solutions To A More Resilient Supply Chain 10/16/2025

    In her opening presentation, Harney noted that there were 98 drug shortages in 2024, 40 medicines in shortage for over three years, and the average duration of a shortage has increased from three years to four years.

  5. Extreme Weather Is Testing Pharma's Resilience — Is It Ready? 10/14/2025

    It may sound like a stretch, but researchers from Harvard University showed how a disproportionate amount of pharmaceutical manufacturers are in areas of climate-driven extreme weather events. Is the pharmaceutical industry currently set up to withstand them?  

  6. Eco-Friendly HBL: Cheaper, Cleaner, And Ready For Pharma 10/6/2025

    Researchers at the University of Maine may have found a way to do two out of three by developing a new method of producing (S)-3-hydroxy-γ-butyrolactone (HBL) for statins, HIV inhibitors and antibiotics that can lower their production cost with an added benefit of reducing their carbon footprint.

  7. Roll Call In The Oral GLP-1 Race 9/26/2025

    The market for GLP-1 agonists is booming and expected to only get bigger. As rates for obesity and cardiovascular disease increase, so too does the demand for GLP-1 drugs.

  8. Pfizer Strengthens Obesity Foothold With Metsera Acquisition 9/22/2025

    After discouraging efforts to bring two oral obesity drugs to market—danuglipron and lotiglipron—this acquisition launches Pfizer back into the obesity therapeutic game.

  9. From Lab to Plant: Managing Operational Environment During Scale-Up 9/18/2025

    Though these challenges can result from equipment, raw material differences, and process variability, operational environments must be a major focus during lab trials, as Yuhei Yamamoto and his team at Takeda learned in a recent experience.

  10. FDA Cracks Down On GLP-1 Imports 9/11/2025

    GLP-1 bulk drug substances must be detained without physical examination (DWPE) unless they are on a list (Green List) of approved foreign GLP-1 manufacturers.